|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 炎症、动脉粥样硬化和心脑血管疾病显示文摘心脑血管疾病的病理基础是动脉粥样硬化,动脉粥样硬化被证实是细胞和分子的炎症反应。临床研究论证了炎症标记C 反应蛋白的增高预测心脑血管病发生的危险。C 反应蛋白已被美国心脏协会和疾病控制中心推荐为目前可信性最高的预测冠心病危险的临床检测指标,使极早期预测心脑血管疾病成为可能。至今发现的抗动脉炎症药物包括:阿司匹林、克皮格尔、他汀类降脂药和血管紧张素转换酶抑制剂。 | 赵莲 薛爽 陈芳 Stan Heptinstall | 2005 | 心血管病学进展2005，26，2： | 10 |
| 2 | Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel显示文摘Background Antiplatelet agents reduce recurrence after cerebral ischaemia but are not effective in all patients,in part because of treatment resistance.The primary aim was to assess the proportion of patients who are insensitive to clopidogrel.The secondary aim was to assess the association between insensitivity to clopidogrel and recurrent cerebrovascular events.Methods Following written informed consent,independent patients with a recent non-cardioembolic ischaemic stroke or transient ischaemic attack,and taking clopidogrel,were enrolled.Platelet function was assessed with remote measurement of surface expression of P-selectin(CD62P)using commercial kits sensitive to aspirin or clopidogrel.Participants’general practitioners provided details on recurrent vascular events at least 90 days later.Data are mean(SD)and median[IQR].Resistance was defined as:aspirin median fluorescence(MF)>500 units,clopidogrel MF>860 units.Non-parametric descriptors and tests were used.Results 63 patients were recruited:mean age 64(13.7)years,women 47%.At baseline,59(95%)patients were taking clopidogrel alone with 3(5%)on combined clopidogrel and aspirin.Assessment of platelet surface P-selectin revealed:aspirin test 528[317,834],>50054.8%;clopidogrel test 429[303,656],>86011.3%.No participants on aspirin and clopidogrel showed aspirin resistance.Thirteen(20.6%)patients had a recurrent cerebrovascular event;those with an ischaemic stroke had a non-significantly higher baseline P-selectin using the clopidogrel test as compared with those with no recurrence:626[380,801]versus 406[265,609],p=0.08.Conclusions Remote measurement of platelet function assessed using the platelet surface expression of P-selectin is feasible.11%of patients taking clopidogrel showed resistance.No significant associations were noted between clopidogrel resistance and recurrent ischaemic events. | Jason Philip Appleton Carla Richardson Natalia Dovlatova Jane May Nikola Sprigg Stan Heptinstall Philip M Bath | 2021 | Stroke & Vascular Neurology2021，6，1： | 2 |
| 3 | Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin显示文摘 | Storey R F May J A Heptinstall S | 2005 | Thromb Res2005，115，4： | 1 |
| 4 | Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery显示文摘 | Evans P A Heptinstall S Crowhurst E C | 2003 | Thromb Haemost2003，1，10： | 1 |
| 5 | Pharmacodynamics,pharmacokinetics,and safety of the oralreversible P2Y12 antagonist AZD6140 with aspirin inpatientswithatherosclerosis:adoubleblindcomparisontoclopidogrelwithaspirin显示文摘 | HustedS Emanuelsson H HeptinstallS etal | 2006 | Eur HeartJ2006，27，9： | 1 |
| 6 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD 6140 with aspirin in patients with atheroselerosis: a double-blind comparison to elopidogrel with aspirin显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
| 7 | Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS) 显示文摘 | Newton CR Graham A Heptinstall LE | 1989 | Nucleic Acids Res1989，17，7： | 1 |
| 8 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atheroscIerosis a double blind comparison to clopidogrel with aspirin 显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
| 9 | Phmxnacodyuamics, phannacoki- netics,aud safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with athemsclerosis : a double-blind comparison to clopidogrel with as- pirin显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
| 10 | Fluorimetric estimation of exo-cellobiohydrolase and 13-D-glucosidase activities in cellulase from Aspergillus fumigatus Fresenius显示文摘 | Heptinstall J Stewart JC Seras M | 1986 | Enzyme and Microbial Technology1986，8，2： | 1 |
| 11 | Analysis of any point mutation in DNA, The amplification refractory mutation system (ARMS) 显示文摘 | Newton CR Graham A Heptinstall LE | 1989 | Nucleic Acids Research1989，17，7： | 1 |
| 12 | Effects of P2Y (1) and P2Y (12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood 显示文摘 | Storey RF Newby I J Heptinstall S | 2001 | Platelets2001，12，7： | 1 |
| 13 | Inhibitory effects of P2Y12 receptor antagonists on TRAP induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes 显示文摘 | Behan M W Fox S C Heptinstall S | 2005 | Platelets2005，16，2： | 1 |
| 14 | Pharmacodynamics,pharmacokinetics,and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
| 15 | Dynamic externl fixation for injuries of the proximal interphalangeal显示文摘 | Bain GI Mehta JA Heptinstall RJ | 1998 | Bone Joint Surg1998，80，： | 1 |
| 16 | Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1显示文摘 | Fox SC Behan MW Heptinstall S | 2004 | Cell Calcium2004，35，1： | 1 |
| 17 | Analysis of any point mutation in DNA, the amplification refractory mutation system(ARMS) 显示文摘 | New C R Graham A Heptinstall L E | 1989 | Nucleic Acids Res1989，17，： | 1 |
| 18 | Current status of stroke prevention in patients with atrial fibrillation 显示文摘 | Bath PMW Zhao L Heptinstall S | 2005 | Eur Heart J Suppl2005，7，8： | 1 |
| 19 | Pharmacodynamics,pharmacokinetics,and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
| 20 | Pharmacody- namics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin显示文摘 | Husted S Emanuelsson H Heptinstall S | 2006 | Eur Heart J2006，27，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员